Aprea Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.1%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 12 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 15 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly46.5MTarget: Sufficient to fund operations into Q1 2028
ACESOT-1051 Trial Patient Enrollment Quarterly22.0Target: At least 50 patients with Uterine Serous Carcinoma (USC) plus Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) patients
Quarterly Operating Loss Quarterly-3.4MTarget: Minimize cash burn through disciplined expense management
Watch Items
- ACESOT-1051 Phase 1 Dose Escalation CompletionTrigger: Transition to Phase 2 or expansion cohortsAction: Complete dose escalation of WEE1 inhibitor APR-1051 by Q2 2027
- ATRN-119 Combination Strategy InitiationTrigger: Finalization of academic and investigator-led study agreementsAction: Initiate combination trials of ATRN-119 with radiation, immuno-oncology therapies, or antibody-drug conjugates
- Reverse Stock Split ExecutionTrigger: Board decision on split ratio (between 1-for-3 and 1-for-8)Action: Implement reverse stock split to maintain NASDAQ listing compliance and appeal to institutional investors
Research as of 20 Jun 2026